Full Press Release Details
Prendergast, MD Michael Lefenfeld Philip Wagenheim Managing Member, Broadband Capital Investments, LLC Formerly President, Pfizer Global Research & Development President and CEO, Hexion, Inc. Former President and CEO, Cyanco Co - founder of SiGNa Chemistry Managing Partner, Broadband Capital Partners, LLC Purnanand Sarma , PhD President & CEO, Immunome Former CEO of Taris Biomedical Sold to Johnson & Johnson in 2019 Former charter Director of the Mayo Center for Individualized Medicine Former member of the Mayo Board of Governors Former member of the Mayo Foundation's Board of Trustees Former Director of the Mayo Clinic Comprehensive Cancer Center Former non - executive member of the Board of Directors, Eli Lilly Richard Baron Former VP and CFO, Zynerba Pharmaceuticals, Inc.
DoD JPEO - CBRND in collaboration with DHA Lead program, Anti IL - 38 Antibody IND Submission Mid - 2023 IL - 38: A novel context dependent immune modulator in multiple solid tumors with poor prognosis Potential indications: squamous carcinomas of head & neck, gastroesophageal and lung Deep Research Pipeline Antibody targeting EPN1: Ectopically expressed, may allow for tumor specific targeting Multiple additional novel targets enabling next - generation modalities (ADCs, T cell engagers) Matthew Robinson, PhD Chief Technology Officer Antibody Structure Function Expert formerly at Fox Chase Cancer Center 26 Experienced Management Team Purnanand Sarma , PhD President & CEO Corleen Roche Chief Financial Officer Dennis Giesing , PhD Chief Development Officer Former CEO of Taris Biomedical Sold to Johnson & Johnson in 2019 Former US CFO, Biogen Former CFO, Global Vaccines, Wyeth/Pfizer Former CSO at Taris Biomedical Led BARDA funded pandemic flu program at MediVector Sandra Stoneman, Esq.
AACR - NCI - EORTC Molecular Targets & Cancer Therapeutics Meeting, October 2021 ( https://doi.org/10.1158/1535 - 7163.TARG - 21 - LBA022 ) Isotype IMM - ONC - 01 50 10 50 mg/Kg Q3D * p < 0.05 In vitro and in vivo preclinical research confirms antitumor activity of IMM - ONC - 01 in solid tumors as a monotherapy Gene expression profiling of patient tumors suggest normal IL - 38 biology is co - opted by tumors of squamous origin to suppress immune infiltration IMM - ONC - 01 exhibits favorable pharmacokinetic profile IMM - ONC - 01 is well tolerated in GLP toxicology studies Potential indications include squamous cell carcinomas, such as head & neck, gastroesophageal and lung IND Submission Anticipated in Mid - 2023 23 IMM - ONC - 01 Program Summary Copyright 2023 Immunome, Inc.
Immunome Internal Data IL - 38 Expression Confirmed in Multiple Tumors of High Unmet Medical Need 1 IL - 38 Overexpression Inhibits Infiltration of T cells into Tumors In Vivo High IL - 38 Expression is Associated with Reduced Immune Cell Infiltration* IL - 38 high tumor samples correlate with reduced infiltration of multiple immune subsets, especially in lung, head & neck, and gastroesophageal cancers IL - 38 Expression is Associated with Reduced Immune Cell Infiltration 21 Copyright 2023 Immunome, Inc.
Sinus Stage III. T3N0M0 SCC of Tongue root Stage II. T2N0M0 ACC of Parotid Stage II. T2N0M0 Isotype Control Anti IL - 38 (Immunome Clone) Weak Moderate Strong Head & Neck Lung, Squamous Esophagus Cervix Skin Lung, Adeno 23% 53% 41% 48% 25% 14% 30% 9% Bladder Prostate log2TPM log2TPM 1. Source: Tempus Real - World Data 2. Cancer Genome Atlas (TCGA) data from Firehouse Legacy dataset 3.
The Antibody Society. Therapeutic monoclonal antibodies approved or in regulatory review. January 14, 2023; www.antibodysociety.org/antibody - therapeutics - product - data . | 2. The Antibody Society. Antibody therapeutics in late - stage clinical studies. January 14, 2023; www.antibodysociety.org/antibodies - in - late - stage - clinical - studies/ Substantial and Sustained Early - Stage ADC Partnering Activity 17 Copyright 2023 Immunome, Inc.
(nM) % C y t o t o x i c i t y Antibody B -Vc-MMAF anti-RSV -Vc-MMAF Unconj. Vc-MMAF Cetuximab-Vc-MMAF Tr a s t u z u m a b ( H e r 2 ) Free MMAF Anti - RSV - VC - MMAF Antibody B - VC - MMAF Cetuximab (EGFR) - VC - MMAF Trastuzumab (Her2) - VC - MMAF Internalization Patient - derived Ab Suitable for ADC Format 0 6 12 18 24 0.0 5 . 0 1 0 4 1 . 0 1 0 5 1 . 5 1 0 5 Ti m e ( h ) R e d t o t a l i n t e g r a t e d i n t e n s i t y / P h a s e A r e a Anti-C1 1orf68 a-RSV Neg Cntrl Antibody B 01 Recent Clinical Success and Approvals Fueling Significant Investment in the ADC Space ADC Market: New Targets and Technologies Likely to Accelerate Growth Significant Number Of Recent ADC Approvals 15 Copyright 2023 Immunome, Inc.
DoD JPEO - CBRND in collaboration with DHA Various Malignancies Oncology, Hematology Auto - Immune Disorders Immunology Immune Disorders Neuroinflammation Neurology Up to 10 novel antibody - target pairs in 3 tumor types Potential Future Therapeutic Areas Immunome Pipeline Targets Identified from Authentic Human Immune Response 8 Copyright 2023 Immunome, Inc.
Nature 577 :549 - 555, 556 - 560, & 561 - 65 (2020) 2. Immunome internal data Cataloging the Context - Dependent B Cell Response Against Cancer We See the Disease Through the Lens of a Memory B Cell Broad Applicability Across Therapeutic Areas Broad Applicability Across Therapeutic Areas Unbiased Interrogation Unveils Targets & Underexplored Biology: Examples 6 Copyright 2023 Immunome, Inc.
PURNANAND SARMA President & CEO, Immunome Immunome's approach has the potential to unlock novel cancer biology and yield multiple therapeutic candidates. STEVE DAVIDSEN VP, Oncology Discovery Research, AbbVie We See the Disease Through the Lens of a Memory B Cell Interrogate Most Educated Components of Immune Response in an Unbiased Manner at Industrial Scale 5 Copyright 2023 Immunome, Inc.
Food and Drug Administration or other governmental authority. No representation is made as to the safety or effectiveness of these current or potential future product candidates for the use for which such product candidates are being studied. This presentation does not constitute an offering of securities of any kind. Powered by Human Memory B Cell Interrogation 3 Immunome: Three - Pronged Strategy Copyright 2023 Immunome, Inc.
These statements and predictions involve risks and uncertainties based on various factors and evolution over time and, therefore, actual dates for these milestones may differ. In this presentation and oral commentary, we may discuss our current and potential future product candidates that have not yet undergone clinical trials or been approved for marketing by the U.S.
While we believe that information provides a reasonable basis for these statements, it may be limited or incomplete and we may have not independently verified it. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review or verification of, all relevant information. We make statements and predictions about future dates for achievement of milestones related to our platform and our programs in this presentation.
Statements that we believe and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based on information available to us as of the date of this presentation, including independent market research, industry publications and surveys, governmental agency publications and other publicly available information.
All statements contained in this presentation are made as of the date specified on the cover, and we undertake no duty to publicly update or revise any such statements, whether as a result of new information, future events or otherwise, except as may be required under applicable law. This presentation may contain product names, trade names, trademarks and service marks of Immunome and of other organizations, which are the properties of their respective owners.
Factors that could cause actual results to differ include, but are not limited to, the following: our ability to execute on our strategy, including with respect to R&D efforts, IND submissions and other regulatory filings, timing of these filings and the timing and nature of governmental authority feedback regarding the same, initiation and completion of any clinical studies, confirmatory testing and other anticipated milestones as and when anticipated; the fact that research and development data are subject to differing interpretations and assessments, including during the peer review/publication process in the scientific community and by regulatory authorities; whether our data will be published in a scientific journal and, if so, when and with what modifications; the effectiveness of our product candidates, including the possibility that further preclinical data and any clinical trial data may be inconsistent with earlier - published data and/or data used for advancing the product candidates; the fact that changes in the profile of the diseases that our programs target could emerge that could impact our ability to address those changes; our ability to fund operations; our reliance on vendors; our ability to execute on our plans for collaborations and partnerships; the competitive landscape; the impact of the COVID - 19 pandemic on our business, operations, strategy, goals and anticipated milestones; and the additional risks and uncertainties set forth more fully under the caption Risk Factors in Immunome's Annual Report on Form 10 - K filed with the United States Securities and Exchange Commission (SEC) on March 28, 2022, and elsewhere in Immunome's Quarterly Reports on form 10 - Q and other filings and reports with the SEC.
Forward - looking statements may be identified by the words anticipate, believe, estimate, expect, intend, plan, project, suggest, may, will, could, should, seek, potential and similar expressions. Forward - looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict.
Former SVP and CFO, Globus Medical Former CFO, various biotech, managed care and generics companies